Preferred Label : Anti-PD-L1/Anti-VEGF Bispecific Antibody Fusion Protein B1962;
NCIt synonyms : Anti-PD-L1/VEGF Bispecific Antibody Fusion Protein B1962; PD-L1/VEGF Bispecific Antibody Fusion Protein B1962; PD-L1 x VEGF Bispecific Antibody Fusion Protein B1962;
NCIt definition : A bispecific antibody fusion protein composed of an immunoglobulin G1 (IgG1) monoclonal
antibody targeting the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1;
cluster of differentiation 274; CD274) and fused to anti-vascular endothelial growth
factor (VEGF) protein, with potential immune checkpoint inhibitory, anti-angiogenic
and antineoplastic activities. Upon administration, anti-PD-L1/anti-VEGF bispecific
antibody fusion protein B1962 targets and simultaneously binds to both PD-L1 and VEGF
expressed on tumor cells. This prevents the binding of PD-L1 to its receptor, programmed
cell death protein 1 (PD-1, CD279), inhibits the PD-1-mediated signaling, and inhibits
the PD-1-mediated downregulation of T-cell activation and proliferation. This restores
and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against VEGF-expressing
tumor cells. The binding of B1962 to VEGF prevents the binding of VEGF to its receptor
VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular
endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease
tumor cell proliferation and prevent metastasis. PD-L1 is overexpressed in many human
cancer cell types and plays an important role in the downregulation of the immune
system and tumor evasion from host immunity. VEGF is overexpressed in a variety of
cancers and is associated with increased invasiveness and decreased survival.;
Molecule name : B 1962; B-1962;
NCI Metathesaurus CUI : CL1905847;
Origin ID : C198689;
concept_is_in_subset
- has_target
